Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis
NCT07190391 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 425
Last updated 2025-09-24
Summary
This study aims to evaluate the efficacy and safety of Apremilast tablets in patients with psoriasis over 32 weeks, through a multicenter, single-arm, open-label, phase 4 clinical trial.
Conditions
Sponsors & Collaborators
-
Daewoong Pharmaceutical Co. LTD.
lead INDUSTRY
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-30
- Primary Completion
- 2026-12-31
- Completion
- 2027-10-31
More Related Trials
-
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
NCT06122649 ·Status: COMPLETED ·Phase: PHASE3
-
Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）
NCT05863273 ·Status: COMPLETED
-
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
NCT00521339 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
NCT01988103 ·Status: COMPLETED ·Phase: PHASE2
-
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
NCT03721172 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00645814 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00195676 ·Status: COMPLETED ·Phase: PHASE3
-
Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast
NCT03442088 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
NCT06088199 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
NCT01925768 ·Status: COMPLETED ·Phase: PHASE3
-
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03611751 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
NCT03236870 ·Status: COMPLETED
-
Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab
NCT03099083 ·Status: COMPLETED
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
NCT02576678 ·Status: COMPLETED ·Phase: PHASE2
-
Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00645892 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
NCT01474512 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain
NCT03539419 ·Status: COMPLETED
-
Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy
NCT03000309 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT01483924 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
NCT04175613 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
NCT02173301 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00645905 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00237887 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
NCT06073119 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219 ·Status: COMPLETED ·Phase: PHASE2